

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
19 May 2016**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

GlaxoSmithKline plc

File No. 1-15170 -- CF# 33627

GlaxoSmithKline plc submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 20-F filed on March 18, 2016.

Based on representations by GlaxoSmithKline plc that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

| | |
|--------------|--------------------------|
| Exhibit 4.8 | through January 27, 2026 |
| Exhibit 4.9 | through January 27, 2026 |
| Exhibit 4.10 | through January 27, 2026 |
| Exhibit 4.12 | through January 27, 2026 |

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary